| 1 | Consumer Staples | XLP | +3.8% |
| 2 | Utilities | XLU | +1.6% |
| 3 | Real Estate | XLRE | +1.0% |
| 4 | Healthcare | XLV | -1.0% |
| 5 | Financials | XLF | -2.6% |
| 6 | Consumer Disc. | XLY | -2.7% |
| 7 | Materials | XLB | -5.8% |
| 8 | Industrials | XLI | -7.1% |
| 9 | Communication | XLC | -8.2% |
| 10 | Energy | XLE | -11.2% |
| 11 | Technology | XLK | -21.0% |
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. …
| Quarter | Date | EPS est. | Actual | Surprise | YoY | Rev. est. | Actual | Surprise | YoY | Copy |
|---|---|---|---|---|---|---|---|---|---|---|
| Q3 '26 | 10/29/267:00 AM | -$1.27 | -$1.32GAAP | -3.9% | -40% | $3.6M | $0 | -100% | -100% | |
| Q2 '26 | 8/5/267:00 AM | -$0.72 | -$0.62GAAP | +13.9% | +35% | $32.6M | $65.0M | +99.6% | +466% | |
| Q1 '26 | 4/30/267:00 AM | -$0.86 | -$0.71GAAP | +17.4% | +13% | $8.8M | $34.4M | ⚠ Check | +55% | |
| Q4 '25 | 2/26/267:00 AM | -$0.78 | -$0.97GAAP | -24.4% | -10% | $16.2M | $2.9M | ⚠ Check | -61% | |
| Q3 '25 | 11/4/257:00 AM | -$0.76 | -$0.90 | -18.4% | -10% | $24.5M | $2.8M | ⚠ Check | -26% | |
| Q2 '25 | 8/11/257:00 AM | -$0.77 | -$0.95GAAP | -23.4% | -64% | $28.3M | $11.5M | -59.4% | -55% | |
| Q1 '25 | 5/9/257:00 AM | -$0.91 | -$0.82GAAP | +9.9% | -19% | $10.7M | $22.1M | +106% | +115% |
⚠ Potential error in calculation, check manually. The two revenue figures may be in different units or currencies.
GAAP = diluted EPS as filed with the SEC. Other EPS figures are adjusted (non-GAAP), the basis analysts estimate.